Risk factor
Very poor trading liquidity
Profitability factor
Favourable price performance
About
Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited primarily focuses on the production and distribution of active pharmaceutical ingredients (APIs) across India. The company also innovates by developing biotechnological processes applicable to the medical, agricultural, and industrial sectors. Its current portfolio includes compounds like androstenedione, lovastatin, and simvastatin, which serve as steroid intermediates and anti-cholesterol agents. Furthermore, Krebs Biochemicals is actively developing new products such as amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine, targeting diverse therapeutic applications including anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough relief. The firm also extends its expertise by offering contract manufacturing services to large pharmaceutical and multinational corporations.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.